[1] Laud PR, Multani AS, Bailey SM, Wu L, Ma J, Kingsley C, Lebel M, Pathak S, DePinho RA, Chang S. Elevated telomere-telomere recombination in WRN-deficient, telomere dysfunctional cells promotes escape from senescence and engagement of the ALT pathway. Genes Dev, 2005, 19(21): 2560–2570.

[2] Chang S, Khoo CM, Naylor ML, Maser RS, DePinho RA. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev, 2003, 17(1): 88–100.

[3] Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J, 1995, 14(17): 4240–4248.

[4] Henderson S, Allsopp R, Spector D, Wang SS, Harley C. In situ analysis of changes in telomere size during replicative aging and cell transformation. J Cell Biol, 1996, 134(1): 1–12.

[5] Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene, 2002, 21(4): 598–610.

[6] Jegou T, Chung I, Heuvelman G, Wachsmuth M, Gorisch SM, Greulich-Bode KM, Boukamp P, Lichter P, Rippe K. Dynamics of telomeres and promyelocytic leukemia nuclear bodies in a telomerase-negative human cell line. Mol Biol Cell, 2009, 20(7): 2070–2082.

[7] Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res, 1999, 59(17): 4175–4179.

[8] Potts PR, Yu H. The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins. Nat Struct Mol Biol, 2007, 14(7): 581–590.

[9] Grobelny JV, Godwin AK, Broccoli D. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J Cell Sci, 2000, 113(Pt 24): 4577–4585.

[10] Jiang WQ, Zhong ZH, Henson JD, Neumann AA, Chang AC, Reddel RR. Suppression of alternative lengthening of telomeres by Sp100-mediated sequestration of the MRE11/RAD50/NBS1 complex. Mol Cell Biol, 2005, 25(7): 2708–2721

[11] Jiang WQ, Zhong ZH, Henson JD, Reddel RR. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene, 2007, 26(32): 4635–4647.

[12] Teng SC, Zakian VA. Telomere-telomere recombination is an efficient bypass pathway for telomere maintenance in Saccharomyces cerevisiae. Mol Cell Biol, 1999, 19(12): 8083–8093.

[13] Marciniak RA, Cavazos D, Montellano R, Chen Q, Guarente L, Johnson FB. A novel telomere structure in a human alternative lengthening of telomeres cell line. Cancer Res, 2005, 65(7): 2730–2737.

[14] Wu L, Multani AS, He H, Cosme-Blanco W, Deng Y, Deng JM, Bachilo O, Pathak S, Tahara H, Bailey SM, Behringer RR, Chang S. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell, 2006, 126(1): 49–62.

[15] Compton SA, Choi JH, Cesare AJ, Ozgur S, Griffith JD. Xrcc3 and Nbs1 are required for the production of extrachromosomal telomeric circles in human alternative lengthening of telomere cells. Cancer Res, 2007, 67(4): 1513–1519.

[16] Muntoni A, Neumann AA, Hills M, Reddel RR. Telomere elongation involves intra-molecular DNA replication in cells utilizing alternative lengthening of telomeres. Hum Mol Genet, 2009, 18(6): 1017–1027.

[17] Cesare AJ, Groff-Vindman C, Compton SA, McEachern MJ, Griffith JD. Telomere loops and homologous recombination- dependent telomeric circles in a Kluyvero-myces lactis telomere mutant strain. Mol Cell Biol, 2008, 28(1): 20–29.

[18] Pickett HA, Cesare AJ, Johnston RL, Neumann AA, Reddel RR. Control of telomere length by a trimming mechanism that involves generation of t-circles. EMBO J, 2009, 28(7): 799–809.

[19] Fasching CL, Bower K, Reddel RR. Telomerase- independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res, 2005, 65(7): 2722–2729.

[20] Jeyapalan JN, Mendez-Bermudez A, Zaffaroni N, Dubrova YE, Royle NJ. Evidence for alternative lengthening of telomeres in liposarcomas in the absence of ALT- associated PML bodies. Int J Cancer, 2008, 122(11): 2414–2421.

[21] Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel RR, Zaffaroni N. Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res, 2006, 66(17): 8918–8924.

[22] Gagos S, Papaioannou G, Chiourea M, Merk-Loretti S, Jefford CE, Mikou P, Irminger-Finger I, Liossi A, Blouin JL, Dahoun S. Unusually stable abnormal karyotype in a highly aggressive melanoma negative for telomerase activity. Mol Cytogenet, 2008, 1(1): 20.

[23] Zhong ZH, Jiang WQ, Cesare AJ, Neumann AA, Wadhwa R, Reddel RR. Disruption of telomere maintenance by depletion of the MRE11/RAD50/NBS1 complex in cells that use alternative lengthening of telomeres. J Biol Chem, 2007, 282(40): 29314–29322.

[24] Saharia A, Stewart SA. FEN1 contributes to telomere stability in ALT-positive tumor cells. Oncogene, 2009, 28(8): 1162–1167.

[25] Amiard S, Doudeau M, Pinte S, Poulet A, Lenain C, Faivre-Moskalenko C, Angelov D, Hug N, Vindigni A, Bouvet P, Paoletti J, Gilson E, Giraud-Panis MJ. A topological mechanism for TRF2-enhanced strand invasion. Nat Struct Mol Biol, 2007, 14(2): 147–154.

[26] Blanco R, Munoz P, Flores JM, Klatt P, Blasco MA. Telomerase abrogation dramatically accelerates TRF2- induced epithelial carcinogenesis. Genes Dev, 2007, 21(2): 206–220.

[27] McEachern MJ, Iyer S. Short telomeres in yeast are highly recombinogenic. Mol Cell, 2001, 7(4): 695–704. [28] Bechard LH, Butuner BD, Peterson GJ, McRae W, Topcu Z, McEachern MJ. Mutant telomeric repeats in yeast can disrupt the negative regulation of recombination-mediated telomere maintenance and create an alternative lengthening of telomeres-like phenotype. Mol Cell Biol, 2009, 29(3): 626–639.

[29] Tilman G, Loriot A, Van Beneden A, Arnoult N, Londono-Vallejo JA, De Smet C, Decottignies A. Subtelomeric DNA hypomethylation is not required for telomeric sister chromatid exchanges in ALT cells. Oncogene, 2009, 28 (14): 1682-1693.

[30] Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA. Methylation of the human telomerase gene CpG island. Cancer Res, 2000, 60(3): 537–541.

[31] Wen J, Cong YS, Bacchetti S. Reconstitution of wild-type or mutant telomerase activity in telomerase-negative immortal human cells. Hum Mol Genet, 1998, 7(7): 1137–1141.

[32] Ford LP, Zou Y, Pongracz K, Gryaznov SM, Shay JW, Wright WE. Telomerase can inhibit the recombination- based pathway of telomere maintenance in human cells. J Biol Chem, 2001, 276(34): 32198–32203.

[33] Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet, 2001, 10(18): 1945–1952.

[34] Chen YJ, Hakin-Smith V, Teo M, Xinarianos GE, Jellinek DA, Carroll T, McDowell D, MacFarlane MR, Boet R, Baguley BC, Braithwaite AW, Reddel RR, Royds JA. Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma. Cancer Res, 2006, 66(13): 6473–6476.